FDA approves first eculizumab biosimilar Bkemv for two rare diseases

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

FDA approves first eculizumab biosimilar Bkemv for two rare diseases

Biosimilars/News | Posted 09/07/2024 0 Post your comment

On 28 May 2024, the US Food and Drug Administration (FDA) approved Amgen's Bkemv (eculizumab-aeeb), the first biosimilar to AstraZeneca's rare blood disorder treatment Soliris approved in the US.

Eculizumab is a humanized monoclonal antibody that is a terminal complement inhibitor. It is approved to treat two rare blood disorders (paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) caused when the immune system attacks and damages red blood cells and platelets. In treatment of people with PNH, it improves quality of life but does not appear to affect the risk of death. It is also indicated for the treatment of patients with aHUS – a disease that primarily affects kidney function – to inhibit complement-mediated thrombotic microangiopathy [1].

Bkemv is approved for the same indications, see below, as the originator, as an interchangeable biosimilar:

the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH) to reduce hemolysis; and
the treatment of patients with aHUS to inhibit complement-mediated thrombotic microangiopathy.

This means it can be substituted for the originator at the pharmacy level, without clinician approval.

The approval comes with a black box warning about the risk of serious infections caused by a bacteria called Neisseria meningitidis.

Bkemv is available only through a restricted programme called the Bkemv Risk Evaluation and Mitigation Strategy (REMS).

The product has already been approved in Europe in 2023 [2]. AstraZeneca acquired the intravenous injection, Soliris, through a US$39 billion buyout of Alexion Pharmaceuticals in 2020. It can now be marketed in the US following a 2020 settlement between Amgen and AstraZeneca/Alexion that prevented the product from reaching the market until 2025 [3].

Advances for Samsung Bioepis’ eculizumab and trastuzumab biosimilars

Phase III trial started in China for eculizumab copy biological

LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: La FDA aprueba el primer biosimilar de eculizumab, Bkemv, para dos enfermedades raras

Browse the news in the Latin American Forum!

FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: La FDA aprueba el primer biosimilar de eculizumab, Bkemv, para dos enfermedades raras

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of eculizumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jul 9]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-eculizumab
2. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of eculizumab biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jul 9]. Available from: www.gabionline.net/biosimilars/news/ema-recommends-approval-of-eculizumab-biosimilar-bekemv
3. GaBI Online - Generics and Biosimilars Initiative. Alexion delays Soliris biosimilar until 2025 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jul 9]. Available from:
www.gabionline.net/policies-legislation/Alexion-delays-Soliris-biosimilar-until-2025

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.